CARMAT has recently participated in two scientific conferences
*A presentation on the use of digital technology in the Company’s total
artificial heart project at the French American Biotech Symposium (FABS
2012) in Nice, France.
*A presentation at the Techno College of the 25^th Annual Meeting of the
European Association for Cardio-Thoracic Surgery in Barcelona, Spain.
PARIS -- October 29, 2012
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most
advanced total artificial heart project, providing an alternative for people
suffering from terminal heart failure, announces that it has presented
scientific publications at the French American Biotech Symposium (FABS 2012)
in Nice on 25 October and the Techno College of the 26^th Annual Meeting of
the European Association for Cardio-Thoracic Surgery (EACTS) in Barcelona on
27 October, 2012.
*Presentation on the theme of the “Contribution of digital technology to
maintaining the autonomy of elderly patients” at FABS 2012, in Nice
This presentation was given by Mr Marcello Conviti, CARMAT’s CEO, on Thursday
25 October 2012 during a session devoted to implants and biomedical
engineering. It notably covered preoperative planning systems using 3D
modelling, physiological self-regulation algorithms and systems intended to
boost the mobility and autonomy of implanted patients.
The 2012 Symposium was organised by Eurobiomed (the healthcare competitive
cluster for the French regions of Provence-Alpes-Côte d’Azur and
Languedoc-Roussillon) and the Office for Science and Technology of the
Consulate General of France in Los Angeles.
*CARMAT was chosen by the EACTS New Technologies committee for a
presentation at the Techno College, the day the conference devotes to
innovation, in Barcelona
This presentation was given by Dr Piet Jansen, CARMAT’s Chief Medical Officer,
on Saturday 27 October 2012 during a session devoted to innovative devices for
treating heart failure. It reported on the specificities of CARMAT’s total
artificial heart project and on the procedural aspects assessed within the
framework of animal testing.
“We are particularly honoured to have been invited, by the EACTS New
Technologies committee, to present our project at the prestigious Techno
College,” said Dr Jansen. “This honour reflects the substantial enthusiasm
shown by European cardio-thoracic surgery specialists for innovation in the
field of chronic heart failure”.
About CARMAT: CARMAT, the world’s most advanced total artificial heart project
The only credible response for all cases of end-stage heart failure - a true
public health issue: CARMAT’s ultimate aim is to provide a response to a major
public health issue associated with cardiovascular disease, the world’s
leading cause of death: heart failure. This disease currently affects over 20
million patients in Europe and the United States. By pursuing the development
of its total artificial heart, CARMAT intends to overcome the well-known
shortfall in heart transplants for the tens of thousands of people suffering
from end-stage heart failure.
The result of combining two types of unique expertise: the medical expertise
of Professor Carpentier, known throughout the world for inventing
Carpentier-Edwards®heart valves - most widely used worldwide - and the
technological expertise of EADS, a global aerospace leader.
Imitating the natural heart: Given its size and weight, the choice of
structural materials and its innovative physiological functions, CARMAT’s
total artificial heart could, assuming upcoming clinical trials are
successful, potentially benefit tens of thousands of patients a year – with no
risk of rejection and providing them with unparalleled quality of life.
A project leader acknowledged at the European level: with the backing of the
European Commission, CARMAT has received the largest grant-in-aid (a total of
€33m) made to an SME by OSEO (the French state innovation agency).
Strongly committed, prestigious founders and shareholders: Truffle Capital
(the leading European venture capital firm), EADS, the Foundation Alain
Carpentier, the Marie Lannelongue Cardiothoracic Centre and thousands of
institutional and individual shareholders have placed their trust in CARMAT.
For further information, visit: www.carmatsa.com
About FABS 2012:
The French American Biotech Symposium was first launched in 2008 by the Office
for Science and Technology of the French Embassy in the United States and is
held each year, alternating between France and the United States. It aims to
promote the exchange of information in terms of innovation in ICT health,
telemedicine, bioengineering, implants, etc. It also strives to develop
networking between French and American experts in these fields and encourage
innovative public-private partnerships between France and the United States.
It targets researchers and scientists from these two countries who are
involved in Research & Development projects, as well as entrepreneurs and
representatives of the ICT and pharmaceutical sectors.
For further information, visit: www.fabs2012.com
This press release and the information contained herein do not constitute an
offer to sell or subscribe to, or a solicitation of an offer to buy or
subscribe to, shares in CARMAT ("the Company") in any country. This press
release contains forward‐looking statements that relate to the Company’s
objectives. Such forward‐looking statements are based solely on the current
expectations and assumptions of the Company’s management and involve risk and
uncertainties. Potential risks and uncertainties include, without limitation,
whether the Company will be successful in implementing its strategies, whether
there will be continued growth in the relevant market and demand for the
Company’s products, new products or technological developments introduced by
competitors, and risks associated with managing growth. The Company’s
objectives as mentioned in this press release may not be achieved for any of
these reasons or due to other risks and uncertainties. No guarantee can be
given as to any of the events anticipated by the forward-looking statements,
which are subject to inherent risks, including those described in the Document
de Référence registered with the Autorité des Marchés Financiers under number
R.12-044 on September 12, 2012 and the Note d’Opération that was approved with
visa no.11-308 on July 11, 2011, changes in economic conditions, the
financial markets or the markets in which Carmat operates. In particular, no
guarantee can be given concerning the Company’s ability to finalize the
development, validation and industrialization of the prosthesis and the
equipment required for its use, to manufacture the prostheses, satisfy the
requirements of the AFSSAPS, enroll patients, obtain satisfactory clinical
results, perform the clinical trials and tests required for CE marking and to
obtain the CE mark.
Valérie Leroy, +33 (0)1 39 45 64 50
Marketing and Investor Relations Director
Caroline Carmagnol, +33 (0)6 64 18 99 59
Financial communication and investor relations
Dusan Oresansky / Emmanuel Huynh, +33 (0)1 44 71 94 94
Press spacebar to pause and continue. Press esc to stop.